

IN THE CLAIMS:

Please substitute the following amended claim for the pending claim with the same number.

LISTING OF CLAIMS:

1. (currently amended) ~~A Non~~ non-effervescent tablet for oral administration of sodium naproxen comprising a tablet core and, if desired, a sugar or film coat on the tablet core, wherein the tablet core consists of 30 to 99% by weight of sodium naproxen and 70 to 1% by weight of auxiliary agent component, comprising at least one basic auxiliary agent, based on the weight of the tablet core.
2. (currently amended) ~~The Tablet~~ tablet as claimed in claim 1, wherein the tablet core consists of 30 to 95% by weight of sodium naproxen and 70 to 5% by weight of auxiliary agent component, based on the weight of the tablet core.
3. (currently amended) ~~The Tablet~~ tablet as claimed in claim ~~1 or~~ 2, wherein the tablet core consists of 60 to 95% by weight of sodium naproxen and 40 to 5% by weight of auxiliary agent component, based on the weight of the tablet core.
4. (currently amended) ~~The Tablet~~ tablet as claimed in ~~any one of claims 1 to~~ claim 3, wherein the tablet core consists of 70 to 93% by weight of sodium naproxen and 30 to 7% by weight of auxiliary agent component, based on the weight of the tablet core.
5. (currently amended) ~~The Tablet~~ tablet as claimed in ~~any one of claims 1 to~~ claim 4, wherein the sodium naproxen has a water content of 0.05 to 14% by weight.
6. (currently amended) ~~The Tablet~~ tablet as claimed in ~~any one of claims 1 to~~ claim 5, wherein the sodium naproxen has a water content of 6 to 12.5% by weight.
7. (currently amended) ~~The Tablet~~ tablet as claimed in ~~any one of claims~~ claim 1 ~~to 6~~, wherein the auxiliary agent component comprises one or more basic auxiliary agents in a total quantity of at least 5% by weight, based on the weight of the tablet

core.

8. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to~~ claim 7, wherein the auxiliary agent component comprises one or more basic auxiliary agents in a total quantity of 10 to 30% by weight, based on the weight of the tablet core.

9. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to 8~~ claim 7, wherein the auxiliary agent component comprises one or more basic auxiliary agents in a total quantity of 15 to 25% by weight, based on the weight of the tablet core.

10. (currently amended) The Tablet tablet as claimed in ~~any one of the claims~~ claim 1 to 9, wherein the basic auxiliary agent is water soluble.

11. (currently amended) The Tablet tablet as claimed in ~~any one of the claims~~ claim 1 to 10, wherein the basic auxiliary agent is selected from basic alkali metal salts, basic alkaline earth metal salts, basic ammonium salts and basic amino acids.

12. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to~~ claim 11, wherein the basic auxiliary agent is selected from sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, trisodium citrate and trisodium phosphate.

13. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to~~ claim 12, wherein the basic auxiliary agent is selected from sodium hydrogen carbonate and potassium hydrogen carbonate.

14. (currently amended) The Tablet tablet as claimed in ~~any one of claims~~ claim 1 to 13, wherein the auxiliary agent component comprises one or more neutral to weakly acidic fillers that improve the compressibility.

15. (currently amended) The Tablet tablet as claimed in ~~any one of claims~~ claim 1 to 14, wherein the auxiliary agent component comprises one or more water soluble,

neutral to weakly acidic fillers that improve the compressibility.

16. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to claim~~ 15, wherein the auxiliary agent component comprises one or more fillers, selected from sugars, hexoses, hydrolysed or enzymatically split starches, cyclodextrins, non-crosslinked polyvinylpyrrolidone, neutral to weakly acidic alkali metal salts, neutral to weakly acidic alkaline earth metal salts, and neutral to weakly acidic ammonium salts.

17. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to claim~~ 16, wherein the auxiliary agent component comprises one or more fillers, selected from hexoses, non-crosslinked polyvinylpyrrolidone, maltodextrin and sodium chloride.

18. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to claim~~ 17, wherein the auxiliary agent component comprises non-crosslinked polyvinylpyrrolidone as filler.

19. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to 18 claim~~ 14, wherein the auxiliary agent component comprises one or more non-water soluble fillers that improve the compressibility and the tablet disintegration.

20. (currently amended) The Tablet tablet as claimed in ~~claim any one of claims 1 to 19,~~ wherein the auxiliary agent component comprises one or more fillers, selected from native and microcrystalline celluloses, starches, modified starches, calcium phosphates and silicon oxide.

21. (currently amended) The Tablet tablet as claimed in ~~any one of claims claim 14 to 20,~~ wherein the proportion of filler is 1 to 50% by weight, based on the weight of the tablet core.

22. (currently amended) The Tablet tablet as claimed in ~~any one of claims claim 14 to 21,~~ wherein the proportion of filler is 3 to 30% by weight, based on the weight of the tablet core.

23. (currently amended) The Tablet tablet as claimed in ~~any one of claims 14 to claim~~ 22, wherein the proportion of filler is 10 to 25% by weight, based on the weight of the tablet core.

24. (currently amended) The Tablet tablet as claimed in ~~any one of claims claim 1 to 23~~, wherein the auxiliary agent component comprises at least one basic auxiliary agent, selected from sodium hydrogen carbonate and potassium hydrogen carbonate, and non-crosslinked polyvinylpyrrolidone as filler.

25. (currently amended) The Tablet tablet as claimed in ~~any one of claims 1 to claim~~ 24, wherein the auxiliary agent component comprises, based on the weight of the tablet core, 5 to 20% by weight of basic auxiliary agent, selected from sodium hydrogen carbonate and potassium hydrogen carbonate, and 5 to 20% by weight of non-crosslinked polyvinylpyrrolidone as filler.

26. (currently amended) A Tablet tablet as claimed in ~~any one of claims claim 1 to 25~~, wherein the auxiliary agent component comprises a disintegrant.

27. (currently amended) A Tablet tablet as claimed in ~~any one of claims claim 1 to 26~~, wherein the auxiliary agent component comprises a disintegrant selected from croscarmellose, crospovidone and crosslinked sodium carboxymethyl starch.

28. (currently amended) A Tablet tablet as claimed in ~~any one of claims claim 1 to 27~~, wherein the auxiliary agent component comprises one or more lubricants and/or glidants.

29. (currently amended) A Tablet tablet as claimed in ~~any one of claims claim 1 to 25~~, wherein the tablet core does not contain any lubricant and does not contain any glidant.

30. (currently amended) A Tablet tablet as claimed in ~~any one of claims claim 1 to 29~~, wherein the auxiliary agent component contains one or more ionic or non-ionic tensides.

31. (currently amended) A Tablet tablet as claimed in ~~any one of claims 1 to~~ claim 30, wherein the auxiliary agent component contains one or more tensides, selected from sodium lauryl sulphate, sodium dodecyl sulphate, polysorbate and saccharose monopalmitate.
32. (currently amended) A Tablet tablet as claimed in ~~claim 30 or 31~~, wherein the proportion of tenside is 0.1 to 5% by weight, based on the weight of the tablet core.
33. (currently amended) A Tablet tablet as claimed in ~~any one of claims~~ claim 1 to 32, wherein the tablet core consists of a granulate with a granular size distribution from 0.25 to 1.25 mm.
34. (currently amended) A Tablet tablet as claimed in ~~any one of the claims~~ claim 1 to 33, wherein the hardness of the tablet core is at least 30 N.
35. (currently amended) A Tablet tablet as claimed in ~~any one of the claims~~ claim 1 to 34 with a content of sodium naproxen of 110 to 660 mg, based on the water-free sodium naproxen.
36. (currently amended) A Tablet tablet as claimed in ~~any one of the claims~~ claim 1 to 13 and 33 to 35, wherein the tablet core consists of sodium naproxen and basic auxiliary agent.
37. (currently amended) A Tablet tablet as claimed in claim 1, comprising sodium naproxen, sodium hydrogen carbonate, microcrystalline cellulose, croscarmellose, talc, and magnesium stearate.
38. (currently amended) A Tablet tablet as claimed in claim 37, comprising 50 to 60 % by weight of sodium naproxen, 15 to 25 % by weight of sodium hydrogen carbonate, 15 to 25 % by weight of microcrystalline cellulose, 2 to 6 % by weight of croscarmellose, 1 to 5 % by weight of talc, and 0.5 to 2.2 % by weight of magnesium stearate.
39. (currently amended) A Tablet tablet as claimed in claim 37, comprising 55 to

65 % by weight of sodium naproxen, 10 to 25 % by weight of sodium hydrogen carbonate, 2 to 15 % by weight of microcrystalline cellulose, 2 to 6 % by weight of croscarmellose, 1 to 5 % by weight of talc, and 0.5 to 2.2 % by weight of magnesium stearate.

40. (currently amended) A Tablet ~~tablet~~ as claimed in claim 39, comprising 55 to 65 % by weight of sodium naproxen, 10 to 25 % by weight of sodium hydrogen carbonate, 5 to 10 % by weight of hydroxyl propyl cellulose, 2 to 15 % by weight of microcrystalline cellulose, 2 to 6 % by weight of croscarmellose, 1 to 5 % by weight of talc, and 0.5 to 2.2 % by weight of magnesium stearate.

41. A process ~~Process~~ for producing a non-effervescent tablet for oral administration of sodium naproxen comprising a tablet core and, if desired, a sugar or film coat on the tablet core, wherein the tablet core consists of 30 to 99% by weight sodium naproxen and 70 to 1% by weight auxiliary agent component, comprising at least one basic auxiliary agent, based on the weight of the tablet core, characterized in that a mixture the sodium naproxen and the auxiliary agent component is compressed into the tablet cores and, if desired, the tablet cores are coated with a sugar or film coat.